Inhalation and Nasal Spray Generic Drugs Market Trends, Regulatory Landscape and Operational Strategies 2015-2023

The global inhalation and nasal generic drugs market features oligopolistic characteristic with a handful of players holding a majority share of the market, observes a new market study by Transparency Market Research (TMR). In 2014, Teva Pharmaceuticals Industries Ltd., Sandoz (Novartis AG), Mylan Laboratories, and Allergan plc held 45.9% of the revenue generated in the global inhalation and nasal spray generics market.

The manufacture of generic drugs is one of the key growth strategies that leading players are adopting to strengthen their positions in the market. This is to cater to untapped regions across the world that display growth potential of the inhalation and nasal spray generic drugs market. For instance, Asia Pacific holds promise for the market expansion of the companies involved.

The global inhalation and nasal spray generic drugs market is expected to be worth US$35 bn by 2023 increasing from US$23 bn in 2016 at a CAGR of 5.5% between 2015 and 2023.

This 100 page report gives readers a comprehensive overview of the inhalation and nasal spray generic drugs market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/inhalation-nasal-spray-generic-drugs.html

Introduction of Generic Drugs to Reduce Healthcare Costs in Asia Pacific

In terms of the drug class, combination sprays are expected to display the highest CAGR at 5.9% between 2015 and 2023.This is due to the high preference for combination sprays for COPD and asthma in most countries. The use of combination sprays and inhalers have proven to be highly effective for the treatment of serious respiratory diseases.

In 2014, North America and Europe stood as the largest markets for generic inhalers and nasal sprays and are expected to retain dominance in the coming years. The large-scale production and consumption of generic inhalers and nasal sprays coupled with strict regulations for patient safety are major factors for the dominance of these regional markets. On the other hand, Asia Pacific is expected to display the fastest growth in the inhalation and nasal spray generic drugs market. In this region, the rapidly evolving healthcare industry, increasing patient pool for asthma and COPD, and the highest population density are reasons for the increased focus of market players in this region. While China and Japan are expected to account for a majority consumption of generic inhalers and nasal sprays, Australia and India are expected to open lucrative growth opportunities to the market due to the increasing efforts from their governments to reduce overall healthcare costs.

Quality Considerations of Generic Drugs Necessitate Implementation of Production Standards in Developing Regions

Generic inhalers and nasal sprays require approval by the U.S. FDA prior to their commercial availability. Generic drugs are usually available at very low prices, thus it is adding the consumer base for these products.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving inhalation and nasal spray generic drugs market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1922

“Patent expiration of standard drugs is the primary reason for the increasing use of generic drugs, says a TMR analyst.” Generic drug manufacturers are reproducing standard drugs at very low prices due to the elimination of the need for marketing and advertising strategies, and most importantly, the elimination of the need for research and development.

The introduction of new generic drugs to the current mix of standard drugs will help reduce healthcare costs globally.

Quality considerations are becoming a concern for the growth of the inhalation and nasal spray generic drugs market in developing economies. The increasing number of drug manufacturers producing their own version of generic inhalers and nasal sprays has led to questions regarding the integrity of generic drugs.

The influx of generic drugs into commercial markets of developing regions has necessitated governments to implement standards for the production and sales of generic drugs. This could have an implication on the revenue generation of this market.

The review presented is based on the findings of a TMR research report, titled “Inhalation and Nasal Spray Generic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.”

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.